Lovastatin delays infection and increases survival rates in AG129 mice infected with Dengue virus serotype 2

Vista sencilla de ítem
dc.contributor.authorMartinez-Gutierrez, Marlen
dc.contributor.authorCorrea-Londoño, Luis A.
dc.contributor.authorCastellanos, Jaime
dc.contributor.authorGallego-Gomez, Juan Carlos
dc.contributor.authorOsorio, Jorge E.
dc.contributor.orcidCastellanos, Jaime [0000-0003-1596-8383]
dc.date.accessioned2020-05-13T20:10:54Z
dc.date.available2020-05-13T20:10:54Z
dc.date.issued2014
dc.description.abstractenglishBackground It has been reported that treatment of DENV-infected cultures with Lovastatin (LOV), can affect viral assembly. The objective of this study was to evaluate the effect of LOV on the survival rate and viremia levels of DENV-2-infected AG129 mice. Methodology/Principal Findings Mice were inoculated with 1×106 plaque-forming units (PFU/ml) of DENV-2 and treated with LOV (200 mg/kg/day). Pre-treatment with one or three doses of LOV increased the survival rate compared to untreated mice (7.3 and 7.1 days, respectively, compared to 4.8 days). Viremia levels also decreased by 21.8% compared to untreated mice, but only in the group administered three doses prior to inoculation. When LOV was administered after viral inoculation, the survival rate increased (7.3 days in the group treated at 24 hpi, 6.8 days in the group treated at 48 hpi and 6.5 days in the group treated with two doses) compared to the untreated group (4.8 days). Interestingly, the serum viral titer increased by 24.6% in mice treated at 48 hpi with a single dose of LOV and by 21.7% in mice treated with two doses (at 24 and 48 hpi) of LOV compared to untreated mice. Finally histopathological changes in the liver and spleen in infected and untreated mice included massive extramedullary erythropoiesis foci and inflammatory filtration, and these characteristics were decreased or absent in LOV-treated mice. Conclusions/Significance Our results suggest that the effect of LOV on viremia depends on the timing of treatment and on the number of doses administered. We observed a significant increase in the survival rate in both schemes due to a delay in the progression of the disease. However, the results obtained in the post-treatment scheme must be handled carefully because this treatment scheme increases viremia and we do not know how this increase could affect disease progression in humans.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0087412
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2710
dc.language.isoeng
dc.publisherPublic Library of Sciencespa
dc.publisher.journalPlos onespa
dc.relation.ispartofseriesPlos one, 1932-6203, Vol. 9, Nro. 2, 2014spa
dc.relation.urihttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087412
dc.rightsAttribution 4.0 International*
dc.rights.creativecommons2014
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.decsLovastatinaspa
dc.subject.decsDenguespa
dc.subject.decsViremiaspa
dc.titleLovastatin delays infection and increases survival rates in AG129 mice infected with Dengue virus serotype 2spa
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Martinez-Gutierrez M., Correa-Londoño L.A., Castellanos J.E., Gallego-Gómez J.C., Osorio J.E._2014.pdf
Tamaño:
13.52 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos